Pan-cancer analysis of the prognostic and immunological role of ANLN: An onco-immunological biomarker

Posted on 05.08.2022 - 15:57

Anillin actin-binding protein (ANLN) is crucially involved in cell proliferation and migration. Moreover, ANLN is significantly in tumor progression in several types of human malignant tumors; however, it remains unclear whether ANLN acts through common molecular pathways within different tumor microenvironments, pathogeneses, prognoses and immunotherapy contexts. Therefore, this study aimed to perform bioinformatics analysis to examine the correlation of ANLN with tumor immune infiltration, immune evasion, tumor progression, immunotherapy, and tumor prognosis. We observed increased ANLN expression in multiple tumors, which could be involved in tumor cell proliferation, migration, infiltration, and prognosis. The level of ANLN methylation and genetic alteration was associated with prognosis in numerous tumors. ANLN facilitates tumor immune evasion through different mechanisms, which involve T-cell exclusion in different cancer types and tumor-infiltrating immune cells in colon adenocarcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, and prostate adenocarcinoma. Additionally, ANLN is correlated with immune or chemotherapeutic outcomes in malignant cancers. Notably, ANLN expression may be a predictive biomarker for the response to immune checkpoint inhibitors. Taken together, our findings suggest that ANLN can be used as an onco-immunological biomarker and could serve as a hallmark for tumor screening, prognosis, individualized treatment design, and follow-up.

CITE THIS COLLECTION

Liu, Kejun; Cui, Lei; Li, Cunquan; Tang, Chaofeng; Niu, Yiming; Hao, Ji; et al. (2022): Pan-cancer analysis of the prognostic and immunological role of ANLN: An onco-immunological biomarker. Frontiers. Collection. https://doi.org/10.3389/fgene.2022.922472
or
Select your citation style and then place your mouse over the citation text to select it.

SHARE

email
need help?